Heterogeneity of regional brain atrophy patterns associated with distinct progression rates in Alzheimer's disease

PLoS ONE

Volumn 10, Issue 11, 2015, Pages

  Byun, Min Soo ^a   Kim, Song E ^a   Park, Jinsick ^b   Yi, Dahyun ^a   Choe, Young Min ^c   Sohn, Bo Kyung ^d   Choi, Hyo Jung ^a   Baek, Hyewon ^a   Han, Ji Young ^a   Woo, Jong Inn ^e   Lee, Dong Young ^a  

^a Seoul National University Hospital   (South Korea)

^b Hanyang University   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

^d Seoul National University Boramae Hospital   (South Korea)

^e Neuroscience Research Institute   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42];

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; BRAIN CORTEX ATROPHY; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FRONTAL CORTEX; GRAY MATTER; HIPPOCAMPUS; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PARIETAL CORTEX; TEMPORAL CORTEX; VOXEL BASED MORPHOMETRY; BRAIN CORTEX; CLASSIFICATION; MIDDLE AGED; PATHOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CEREBRAL CORTEX; FEMALE; GRAY MATTER; HIPPOCAMPUS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED;

EID: 84957599672     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0142756     Document Type: Article

References (55)

1. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984; 34(7):939-44. PMID: 6610841.
2. Beach TG, Monsell SE, Phillips LE, Kukull W. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. Journal of neuropathology and experimental neurology. 2012; 71(4):266-73. doi:10.1097/NEN.0b013e31824b211b PMID: 22437338.
3. Bradford A, Kunik ME, Schulz P, Williams SP, Singh H. Missed and delayed diagnosis of dementia in primary care: prevalence and contributing factors. Alzheimer disease and associated disorders. 2009; 23(4):306-14. doi:10.1097/WAD.0b013e3181a6bebc PMID: 19568149.
4. Jack CR Jr., Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & dementia: The journal of the Alzheimer's Association. 2011; 7(3):257-62. doi:10.1016/j.jalz.2011.03.004 PMID: 21514247.
5. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr., Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & dementia: The journal of the Alzheimer's Association. 2011; 7(3):263-9. doi:10.1016/j.jalz.2011.03.005 PMID: 21514250.
6. Dickerson BC, Bakkour A, Salat DH, Feczko E, Pacheco J, Greve DN, et al. The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cerebral cortex. 2009; 19 (3):497-510. doi:10.1093/cercor/bhn113 PMID: 18632739.
7. Frisoni GB, Fox NC, Jack CR Jr., Scheltens P, Thompson PM. The clinical use of structural MRI in Alzheimer disease. Nature reviews Neurology. 2010; 6(2):67-77doi:10.1038/nrneurol.2009.215 PMID: 20139996.
8. Scheltens P, Fox N, Barkhof F, De Carli C. Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion. Lancet neurology. 2002; 1(1):13-21. PMID: 12849541.
9. Thompson PM, Hayashi KM, de Zubicaray G, Janke AL, Rose SE, Semple J, et al. Dynamics of gray matter loss in Alzheimer's disease. The Journal of neuroscience: The official journal of the Society for Neuroscience. 2003; 23(3):994-1005. PMID: 12574429.
10. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta neuropathologica. 1991; 82(4):239-59. PMID: 1759558.
11. Whitwell JL, Shiung MM, Przybelski SA, Weigand SD, Knopman DS, Boeve BF, et al. MRI patterns of atrophy associated with progression to AD in amnestic mild cognitive impairment. Neurology. 2008; 70 (7):512-20. doi:10.1212/01.wnl.0000280575.77437.a2 PMID: 17898323.
12. Jack CR Jr., Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet neurology. 2010; 9(1):119-28. doi:10.1016/S1474-4422(09)70299-6 PMID: 20083042.
13. Jack CR Jr., Petersen RC, O'Brien PC, Tangalos EG. MR-based hippocampal volumetry in the diagnosis of Alzheimer's disease. Neurology. 1992; 42(1):183-8. PMID: 1734300.
14. Visser PJ, Scheltens P, Verhey FR, Schmand B, Launer LJ, Jolles J, et al. Medial temporal lobe atrophy and memory dysfunction as predictors for dementia in subjects with mild cognitive impairment. Journal of neurology. 1999; 246(6):477-85. PMID: 10431775.
15. Yavuz BB, Ariogul S, Cankurtaran M, Oguz KK, Halil M, Dagli N, et al. Hippocampal atrophy correlates with the severity of cognitive decline. International psychogeriatrics/IPA. 2007; 19(4):767-77. doi:10.1017/S1041610206004303 PMID: 17005070.
16. Teipel SJ, Grothe M, Lista S, Toschi N, Garaci FG, Hampel H. Relevance of magnetic resonance imaging for early detection and diagnosis of Alzheimer disease. The Medical clinics of North America. 2013; 97(3):399-424. doi:10.1016/j.mcna.2012.12.013 PMID: 23642578.
17. Cash DM, Rohrer JD, Ryan NS, Ourselin S, Fox NC. Imaging endpoints for clinical trials in Alzheimer's disease. Alzheimer's research & therapy. 2014; 6(9):87. doi:10.1186/s13195-014-0087-9 PMID: 25621018.
18. Douaud G, Refsum H, de Jager CA, Jacoby R, Nichols TE, Smith SM, et al. Preventing Alzheimer's disease- related gray matter atrophy by B-vitamin treatment. Proceedings of the National Academy of Sciences of the United States of America. 2013; 110(23):9523-8. doi:10.1073/pnas.1301816110 PMID: 23690582.
19. Lowe VJ, Peller PJ, Weigand SD, Montoya Quintero C, Tosakulwong N, Vemuri P, et al. Application of the National Institute on Aging-Alzheimer's Association AD criteria to ADNI. Neurology. 2013; 80 (23):2130-7. doi:10.1212/WNL.0b013e318295d6cf PMID: 23645596.
20. Murray ME, Graff-Radford NR, Ross OA, Petersen RC, Duara R, Dickson DW. Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: A retrospective study. Lancet neurology. 2011; 10(9):785-96. doi:10.1016/S1474-4422(11)70156-9 PMID: 21802369.
21. Whitwell JL, Dickson DW, Murray ME, Weigand SD, Tosakulwong N, Senjem ML, et al. Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: A case-control study. Lancet neurology. 2012; 11(10):868-77. doi:10.1016/S1474-4422(12)70200-4PMID: 22951070.
22. Brewer JB. Fully-automated volumetric MRI with normative ranges: Translation to clinical practice. Behavioural neurology. 2009; 21(1):21-8. doi:10.3233/BEN-2009-0226PMID: 19847042.
23. Bakkour A, Morris JC, Wolk DA, Dickerson BC. The effects of aging and Alzheimer's disease on cerebral cortical anatomy: Specificity and differential relationships with cognition. NeuroImage. 2013; 76:332-44. doi:10.1016/j.neuroimage.2013.02.059 PMID: 23507382.
24. Taki Y, Thyreau B, Kinomura S, Sato K, Goto R, Wu K, et al. A longitudinal study of age- And genderrelated annual rate of volume changes in regional gray matter in healthy adults. Human brain mapping. 2013; 34(9):2292-301. doi:10.1002/hbm.22067PMID: 22438299.
25. Shiino A, Watanabe T, Maeda K, Kotani E, Akiguchi I, Matsuda M. Four subgroups of Alzheimer's disease based on patterns of atrophy using VBM and a unique pattern for early onset disease. Neuro- Image. 2006; 33(1):17-26. doi:10.1016/j.neuroimage.2006.06.010 PMID: 16904912.
26. Duara R, Loewenstein DA, Shen Q, Barker W, Greig MT, Varon D, et al. Regional patterns of atrophy on MRI in Alzheimer's disease: Neuropsychological features and progression rates in the ADNI cohort. Advances in Alzheimer's Disease. 2013; 2(4):135-47. doi:10.4236/aad.2013.24019.
27. Noh Y, Jeon S, Lee JM, Seo SW, Kim GH, Cho H, et al. Anatomical heterogeneity of Alzheimer disease: based on cortical thickness on MRIs. Neurology. 2014; 83(21):1936-44. doi:10.1212/WNL.0000000000001003 PMID: 25344382.
28. Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ, et al. Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology. 2010; 74(3):201-9. doi:10.1212/WNL.0b013e3181cb3e25 PMID: 20042704.
29. Crane PK, Carle A, Gibbons LE, Insel P, Mackin RS, Gross A, et al. Development and assessment of a composite score for memory in the Alzheimer's Disease Neuroimaging Initiative (ADNI). Brain imaging and behavior. 2012; 6(4):502-16. doi:10.1007/s11682-012-9186-z PMID: 22782295.
30. Gibbons LE, Carle AC, Mackin RS, Harvey D, Mukherjee S, Insel P, et al. A composite score for executive functioning, validated in Alzheimer's Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment. Brain imaging and behavior. 2012; 6(4):517-27. doi:10.1007/s11682-012-9176-1PMID: 22644789.
31. Jack CR Jr., Bernstein MA, Fox NC, Thompson P, Alexander G, Harvey D, et al. The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. Journal of magnetic resonance imaging: JMRI. 2008; 27(4):685-91. doi:10.1002/jmri.21049 PMID: 18302232.
32. Desikan RS, Segonne F, Fischl B, Quinn BT, Dickerson BC, Blacker D, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. NeuroImage. 2006; 31(3):968-80. doi:10.1016/j.neuroimage.2006.01.021 PMID: 16530430.
33. Pauker JD. Constructing overlapping cell tables to maximize the clinical usefulness of normative test data: rationale and an example from neuropsychology. Journal of clinical psychology. 1988; 44(6):930- 3. PMID: 3216017.
34. Ivnik RJ, Malec J.F., Tangalos E.G. The Auditory-Verbal Learning Test (AVLT): Norms for Ages 55 years or older. Psychological assessment. 1990; 2(3):304-12.
35. Lee DY, Lee KU, Lee JH, Kim KW, Jhoo JH, Kim SY, et al. A normative study of the CERAD neuropsychological assessment battery in the Korean elderly. Journal of the international neuropsychological society: JINS. 2004; 10(1):72-81. doi:10.1017/S1355617704101094 PMID: 14751009.
36. Seo EH, Lee DY, Choo IH, Kim SG, Kim KW, Youn JC, et al. Normative study of the Stroop Color and Word Test in an educationally diverse elderly population. International journal of geriatric psychiatry. 2008; 23(10):1020-7. doi:10.1002/gps.2027 PMID: 18425990.
37. Fillenbaum GG, Burchett BM, Unverzagt FW, Rexroth DF, Welsh-Bohmer K. Norms for CERAD constructional praxis recall. The Clinical neuropsychologist. 2011; 25(8):1345-58. doi:10.1080/13854046.2011.614962 PMID: 21992077.
38. Caban-Holt A, Abner E, Kryscio RJ, Crowley JJ, Schmitt FA. Age-expanded normative data for the Ruff 2&7 Selective Attention Test: evaluating cognition in older males. The Clinical neuropsychologist. 2012; 26(5):751-68. doi:10.1080/13854046.2012.690451 PMID: 22651854.
39. Han JY, Seo EH, Yi D, Sohn BK, Choe YM, Byun MS, et al. A normative study of total scores of the CERAD neuropsychological assessment battery in an educationally diverse elderly population. International psychogeriatrics/IPA. 2014; 26(11):1897-904. doi:10.1017/S1041610214001379 PMID: 25075438.
40. Heister D, Brewer JB, Magda S, Blennow K, McEvoy LK, Initiative AsDN. Predicting MCI outcome with clinically available MRI and CSF biomarkers. Neurology. 2011; 77(17):1619-28. doi:10.1212/WNL.0b013e3182343314 PMID: 21998317.
41. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Annals of neurology. 2009; 65(4):403-13. doi:10.1002/ana.21610 PMID: 19296504.
42. Jagust WJ, Landau SM, Shaw LM, Trojanowski JQ, Koeppe RA, Reiman EM, et al. Relationships between biomarkers in aging and dementia. Neurology. 2009; 73(15):1193-9. doi:10.1212/WNL.0b013e3181bc010c PMID: 19822868.
43. Dickerson BC, Wolk DA, Alzheimer's Disease Neuroimaging I. Dysexecutive versus amnesic phenotypes of very mild Alzheimer's disease are associated with distinct clinical, genetic and cortical thinning characteristics. Journal of neurology, neurosurgery, and psychiatry. 2011; 82(1):45-51. doi:10.1136/jnnp.2009.199505PMID: 20562467.
44. Terry RD, Hansen LA, DeTeresa R, Davies P, Tobias H, Katzman R. Senile dementia of the Alzheimer type without neocortical neurofibrillary tangles. Journal of neuropathology and experimental neurology. 1987; 46(3):262-8. PMID: 2881985.
45. Hansen LA, Masliah E, Galasko D, Terry RD. Plaque-only Alzheimer disease is usually the lewy body variant, and vice versa. Journal of neuropathology and experimental neurology. 1993; 52(6):648-54. PMID: 8229084.
46. Tiraboschi P, Hansen LA, Thal LJ, Corey-Bloom J. The importance of neuritic plaques and tangles to the development and evolution of AD. Neurology. 2004; 62(11):1984-9. PMID: 15184601.
47. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002; 297(5580):353-6. doi:10.1126/science.1072994 PMID: 12130773.
48. Jack CR Jr., Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer's disease: An updated hypothetical model of dynamic biomarkers. Lancet neurology. 2013; 12(2):207-16. doi:10.1016/S1474-4422(12)70291-0PMID: 23332364.
49. La Joie R, Landeau B, Perrotin A, Bejanin A, Egret S, Pelerin A, et al. Intrinsic connectivity identifies the hippocampus as a main crossroad between Alzheimer's and semantic dementia-targeted networks. Neuron. 2014; 81(6):1417-28. doi:10.1016/j.neuron.2014.01.026 PMID: 24656258.
50. Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. The Journal of neuroscience: The official journal of the Society for Neuroscience. 2005; 25(34):7709-17. doi:10.1523/JNEUROSCI.2177-05.2005 PMID: 16120771.
51. Lehmann M, Ghosh PM, Madison C, Laforce R Jr., Corbetta-Rastelli C, Weiner MW, et al. Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer's disease. Brain: A journal of neurology. 2013; 136(Pt 3):844-58. doi:10.1093/brain/aws327 PMID: 23358601.
52. Sheline YI, Raichle ME, Snyder AZ, Morris JC, Head D, Wang S, et al. Amyloid plaques disrupt resting state default mode network connectivity in cognitively normal elderly. Biological psychiatry. 2010; 67 (6):584-7. doi:10.1016/j.biopsych.2009.08.024 PMID: 19833321.
53. Hake A, Trzepacz PT, Wang S, Yu P, Case M, Hochstetler H, et al. Florbetapir positron emission tomography and cerebrospinal fluid biomarkers. Alzheimer's & dementia: The journal of the Alzheimer's Association. 2015; 11(8):986-93. doi:10.1016/j.jalz.2015.03.002 PMID: 25916563.
54. Li QX, Villemagne VL, Doecke JD, Rembach A, Sarros S, Varghese S, et al. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-beta Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. Journal of Alzheimer's disease: JAD. 2015; 48(1):175-87. doi:10.3233/JAD-150247 PMID: 26401938.
55. Okamura N, Furumoto S, Fodero-Tavoletti MT, Mulligan RS, Harada R, Yates P, et al. Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET. Brain: A journal of neurology. 2014; 137(Pt 6):1762-71. doi:10.1093/brain/awu064PMID: 24681664.